ReviewThe Journal of antimicrobial chemotherapy2010
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Review in The Journal of antimicrobial chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it, 213 citations in OpenAlex.
- Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.Antimicrobial agents and chemotherapy · 2013Pooled it
- Pharmacodynamic Effect of Different Dosage Regimes of Oseltamivir in Severe Influenza Patients Requiring Mechanical Ventilation: A Multicentre Randomised Controlled Trial.Influenza and other respiratory viruses · 2025Trial
- Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.Clinical pharmacokinetics · 2018Trial
- Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.Journal of Korean medical science · 2017Trial
- Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers.Drug design, development and therapy · 2017Trial
- Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.British journal of clinical pharmacology · 2015Trial
- Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.Antimicrobial agents and chemotherapy · 2014Trial
- Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.Antimicrobial agents and chemotherapy · 2012Trial
- Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.Antimicrobial agents and chemotherapy · 2012Trial
- Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.Antimicrobial agents and chemotherapy · 2011Trial
- Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.Antimicrobial agents and chemotherapy · 2011Trial
- Influence of Spacer Chains Derived from Ring-Opened Crown Ethers on the Anti-Influenza A Virus Activity ofMolecules (Basel, Switzerland) · 2026Article
- Antiviral Resistance Associated With Multiple Mutations Occurring in Seasonal Influenza A(H3N2) Virus in a Patient Treated With Oseltamivir.Clinical case reports · 2026Article
- Management of Newborns Exposed to Maternal Influenza: A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Biphasic Metabolic Control of Shikimic Acid Production inACS omega · 2026Article
- In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.Archives of virology · 2026Article
- Article
- Modeling viral shedding and symptom outcomes in oseltamivir-treated experimental influenza infection.PloS one · 2026Article
- A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance.Nature communications · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication. Treatment of infected children > or =1 year and adults of all ages may decrease the severity and duration of the symptoms of infection, while prophylactic dosing can prevent their onset. Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication. The pharmacokinetics of oseltamivir and oseltamivir carboxylate are dose proportional after repeated doses of up to 500 mg twice daily. This predictable profile means that oseltamivir is suitable for use in diverse patient populations, which may include young children and elderly patients, various ethnic groups and those with renal or hepatic impairment. As the potential for drug interactions is low, oseltamivir is also suitable for use in patients with co-morbid conditions who are likely to be receiving concomitant medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.